Cargando…

The role of TGF-β pathway alterations in immune regulation as a potential pan-cancer biomarker in immunotherapy

BACKGROUND: Depending on the context, the transforming growth factor beta (TGF-β) signaling pathway is involved in opposing cell processes of tumor suppression and tumor promotion. However, the effects of TGF-β pathway on immunotherapy efficacy have not yet been systematically investigated. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Yan, Li, Wei, Qian, Bing, Ming, Jie, Zhao, Zhengyi, Yan, Zhengqing, Zhao, Xiaochen, Chen, Shiqing, Yin, Yongmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667138/ https://www.ncbi.nlm.nih.gov/pubmed/34988169 http://dx.doi.org/10.21037/atm-21-5138

Ejemplares similares

Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients
por: Zuo, Wei, et al.
Publicado: (2020)

Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes
por: Jiang, Tao, et al.
Publicado: (2020)

RelB is a potential molecular biomarker for immunotherapy in human pan-cancer
por: Wu, Jintao, et al.
Publicado: (2023)

Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction
por: Li, Huanyu, et al.
Publicado: (2023)

A pan‐cancer blueprint of genomics alterations and transcriptional regulation of Siglecs, and implications in prognosis and immunotherapy responsiveness
por: Mei, Song, et al.
Publicado: (2023)

Protocol to identify novel immunotherapy biomarkers based on transcriptomic data in human cancers
por: Mei, Jie, et al.
Publicado: (2023)

Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy
por: Liu, Jinhui, et al.
Publicado: (2022)

Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis
por: Zhao, Guang, et al.
Publicado: (2022)

A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
por: Yang, Jing, et al.
Publicado: (2022)

TGFβ: Signaling Blockade for Cancer Immunotherapy
por: Chen, Szu-Ying, et al.
Publicado: (2022)

Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma
por: Yu, Qian, et al.
Publicado: (2022)

TGFβ2 is a Prognostic Biomarker for Gastric Cancer and is Associated With Methylation and Immunotherapy Responses
por: Han, Bangling, et al.
Publicado: (2022)

Regulation of TGF-β Signal Transduction
por: Zhao, Bing, et al.
Publicado: (2014)

TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
por: Dahmani, Amina, et al.
Publicado: (2018)

NK Cell Metabolism and TGFβ – Implications for Immunotherapy
por: Slattery, Karen, et al.
Publicado: (2019)

Targeting immunosuppression by TGF-β1 for cancer immunotherapy
por: de Streel, Grégoire, et al.
Publicado: (2021)

KNSTRN, a Poor Prognostic Biomarker, Affects the Tumor Immune Microenvironment and Immunotherapy Outcomes in Pan-Cancer
por: Zhang, Wanli, et al.
Publicado: (2023)

The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy
por: Chen, Siyuan, et al.
Publicado: (2021)

YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
por: Hu, Jian, et al.
Publicado: (2021)

Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report
por: Qian, Bing, et al.
Publicado: (2022)

PKR induces TGF-β and limits oncolytic immune therapy
por: Hong, Bangxing, et al.
Publicado: (2023)

Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers
por: Cai, Yuan, et al.
Publicado: (2022)

Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker
por: Tang, Yumei, et al.
Publicado: (2023)

Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy
por: Tschernia, Nicholas P., et al.
Publicado: (2022)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
por: Jiang, Tao, et al.
Publicado: (2020)

Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker
por: Xie, Pan, et al.
Publicado: (2022)

Pan-Cancer Analysis of the Oncogenic and Immunological Role of RCN3: A Potential Biomarker for Prognosis and Immunotherapy
por: Ding, Jian, et al.
Publicado: (2022)

BRCA1-Associated Protein Is a Potential Prognostic Biomarker and Is Correlated With Immune Infiltration in Liver Hepatocellular Carcinoma: A Pan-Cancer Analysis
por: Ju, Qiang, et al.
Publicado: (2020)

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures
por: Zhang, Xinke, et al.
Publicado: (2021)

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
por: Louie, Bryan H., et al.
Publicado: (2022)

Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker
por: Deng, Xinna, et al.
Publicado: (2023)

DHRS7 is an immune-related prognostic biomarker of KIRC and pan-cancer
por: Tang, Sheng, et al.
Publicado: (2022)

Pan-Cancer Study on Protein Kinase C Family as a Potential Biomarker for the Tumors Immune Landscape and the Response to Immunotherapy
por: Abdelatty, Alaa, et al.
Publicado: (2022)

IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma
por: Liu, Chengdong, et al.
Publicado: (2022)

The influences of TGF-β1 upon the human adenocarcinoma cell of lung A549 and cellular immunity
por: Li, Min-Jie, et al.
Publicado: (2020)

Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis
por: Zhao, Yaqi, et al.
Publicado: (2022)

Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder Cancer
por: Benjamin, David J., et al.
Publicado: (2021)

BFAR coordinates TGFβ signaling to modulate Th9-mediated cancer immunotherapy
por: Pei, Siyu, et al.
Publicado: (2021)

TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
por: Chakravarthy, Ankur, et al.
Publicado: (2018)

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition
por: Ni, Ying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9mdl45pjkkfp2g05mju8c86ohj